Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine vs BCG in NMIBC
NCT05626101Recruiting
- Sponsor
- Al-Azhar University
- Start
- Jan 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of gemcitabine in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Al-Azhar University. Primary endpoints: Recurrence Free Survival at 2 years and Progression Free Survival at 2 years. Started Jan 2021; status: recruiting.
02
Drugs
gemcitabine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05626101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626101.